生殖支原体大环内酯类和氟喹诺酮类耐药相关突变的流行率:系统综述与荟萃分析
该系统综述与荟萃分析汇总了21个国家59项研究,评估生殖支原体对大环内酯类和氟喹诺酮类耐药相关突变的流行率。
核心结论
- 全球生殖支原体大环内酯类耐药突变流行率高且随时间显著上升,氟喹诺酮类耐药突变流行率较低但存在地区差异,双重耐药不常见。
- 亟需全球监测和优化治疗措施,包括耐药导向策略、新抗菌药物和联合方案,以确保高治愈率并防止耐药株传播。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase和MEDLINE截至2019年1月7日发表的所有语言研究。
- 纳入59项来自21个国家的研究:57项大环内酯类耐药(8966份样本)、25项氟喹诺酮类耐药(4003份样本)、22项双重耐药(3280份样本)。
- 采用随机效应荟萃分析计算汇总估计值,按WHO区域和时间段进行亚组和荟萃回归分析。
主要发现
- 大环内酯类耐药突变在西太平洋和美洲区域的流行率显著高于欧洲区域。
关键数值与推荐
- 大环内酯类耐药相关突变定义:23S rRNA基因第2058或2059位点与阿奇霉素耐药相关的关键突变。
- 氟喹诺酮类耐药相关突变定义:parC基因S83R、S83I、D87N或D87Y与莫西沙星耐药相关的关键突变。
- 流行率定义为成功鉴定的生殖支原体样本中携带上述突变的样本比例。
临床怎么用
- 在生殖支原体感染治疗中应考虑大环内酯类耐药的高流行率,尤其在2016-17年及西太平洋和美洲区域。
- 推荐采用耐药导向的治疗策略以提高治愈率并减少耐药株传播。
- 临床应关注氟喹诺酮类耐药的地域差异,西太平洋区域需警惕其较高流行率。
局限性
- 研究仅纳入截至2019年1月7日发表的数据,未覆盖更近期趋势。
- 各研究间样本鉴定方法和突变检测方法可能存在异质性。
- 部分WHO区域研究数量有限,可能影响区域间比较的可靠性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mycoplasma genitalium is now recognised as an important bacterial sexually transmitted infection. We summarised data from studies of mutations associated with macrolide and fluoroquinolone resistance in M genitalium to establish the prevalence of resistance. We also investigated temporal trends in resistance and aimed to establish the association between resistance and geographical location. METHODS: In this systematic review and meta-analysis, we searched PubMed, Embase, and MEDLINE for studies that included data for the prevalence of mutations associated with macrolide and fluoroquinolone resistance in M genitalium published in any language up to Jan 7, 2019. We defined prevalence as the proportion of M genitalium samples positive for key mutations associated with azithromycin resistance (23S rRNA gene, position 2058 or 2059) or moxifloxacin resistance (S83R, S83I, D87N, or D87Y in parC), or both, among all M genitalium samples that were successfully characterised. We used random-effects meta-analyses to calculate summary estimates of prevalence. Subgroup and meta-regression analyses by WHO region and time period were done. This study was registered with PROSPERO, number CRD42016050370. RESULTS: Overall, 59 studies from 21 countries met the inclusion criteria for our study: 57 studies of macrolide resistance (8966 samples), 25 of fluoroquinolone resistance (4003 samples), and 22 of dual resistance to macrolides and fluoroquinolones (3280 samples). The summary prevalence of mutations associated with macrolide resistance among M genitalium samples was 35·5% (95% CI 28·8-42·5); prevalence increased from 10·0% (95% CI 2·6-20·1%) before 2010, to 51·4% (40·3-62·4%) in 2016-17 (p<0·0001). Prevalence of mutations associated with macrolide resistance was significantly greater in samples in the WHO Western Pacific and Americas regions than in those from the WHO European region. The overall prevalence of mutations associated with fluoroquinolone resistance in M genitalium samples was 7·7% (95% CI 4·5-11·4%). Prevalence did not change significantly over time, but was significantly higher in the Western Pacific region than in the European region. Overall, the prevalence of both mutations associated with macrolide resistance and those associated with fluoroquinolone resistance among M genitalium samples was 2·8% (1·3-4·7%). The prevalence of dual resistance did not change significantly over time, and did not vary significantly by geographical region. INTERPRETATION: Global surveillance and measures to optimise the efficacy of treatments-including resistance-guided strategies, new antimicrobials, and antimicrobial combination approaches-are urgently needed to ensure cure in a high proportion of M genitalium infections and to prevent further spread of resistant strains. FUNDING: Australian National Health and Medical Research Council.
引用
- Machalek DA, Tao Y, Shilling H, et al. Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis. Lancet Infect Dis. 2020. PMID: 32622378. doi:10.1016/S1473-3099(20)30154-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。